Global Febrile Neutropenia Price 2025, Forecast To 2034
26 Mar, 2025
What Has Been the Progress and Growth of the Febrile Neutropenia Market in Recent Years?
The febrile neutropenia market has seen considerable growth due to a variety of factors.
• The market size for febrile neutropenia has seen a robust growth in the previous years. It is set to grow from $10.60 billion in 2024 to $11.31 billion in 2025, with a compound annual growth rate (CAGR) of 6.7%.
The growth in the past period is due to several reasons such as the increasing occurrence of cancer, the increasing use of chemotherapy, the advancement of personalized medications, reduction in healthcare costs, and an increased prevalence of neutropenia.
What Is The Expected Growth In The Febrile Neutropenia Market Size Evolve over the Forecast Period?
The febrile neutropenia market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for febrile neutropenia is predicted to experience robust expansion over the coming years, with a projected valuation of $14.48 billion by 2029, evidencing a compound annual growth rate (CAGR) of 6.4%.
Factors fuelling this predicted growth during the forecast period include a surge in the usage of immunosuppressive drugs, rising R&D activities, supportive reimbursement schemes, augmented financial investments, and an escalation in leukemia incidents. Major trends forecasted for this timeframe include accelerated molecular diagnostics, antimicrobial stewardship and de-escalation therapy adoption, targeted treatments and immunotherapy, risk stratification models, along with advances in fungal biomarkers.
Gain Insights Into The Febrile Neutropenia Global Market Report 2025 With A Free Sample Report Here:
What Main Forces Are Fueling Expansion In The Febrile Neutropenia Market?
The rise in cancer cases is speculated to boost the advancement of the febrile neutropenia market. Cancer is a multifaceted cluster of diseases marked by uncontrollable and abnormal cell growth that can infest surrounding tissues and metastasize to different body parts. Its growing prevalence is attributed to varied reasons such as increasing age, exposure to environmental & occupational hazards, genetic tendencies, as well as hormonal & reproductive elements. Febrile neutropenia proves beneficial for cancer patients by underlining the elevated risk of infections amid chemotherapy, thereby encouraging proactive intervention and specific treatments to avert serious complications. This improves patient outcomes and ensures uninterrupted cancer treatment. For example, as reported by the American Cancer Society, a non-profit organization working for cancer awareness based in the US, in January 2022, around 1.9 million fresh cancer cases and about 609,360 cancer-associated deaths are predicted in the US, averaging around 1,670 deaths every day. Hence, the growing number of cancer cases is influencing the expansion of the febrile neutropenia market.
What Are The Primary Segments In The Global Febrile Neutropenia Market?
The febrile neutropenia market covered in this report is segmented –
1) By Treatment: Empirical Antibiotic Therapy, Targeted Antibiotic Therapy, Supportive Care
2) By Risk Factors: Chemotherapy-Induced Neutropenia, Transplant-Related Neutropenia, Genetic Disorders
3) By Etiology: Gram-Negative Bacteria, Gram-Positive Bacteria, Fungal Infections, Viral Infections
4) By Diagnostic Methods: Blood Cultures, Imaging Tests, Bone Marrow Aspiration
Subsegments:
1) By Empirical Antibiotic Therapy: Broad-Spectrum Beta-Lactams, Glycopeptides, Carbapenems
2) By Targeted Antibiotic Therapy: Antifungal Therapy, Antiviral Therapy, Gram-Positive Bacterial Therapy, Gram-Negative Bacterial Therapy
3) By Supportive Care: Granulocyte Colony-Stimulating Factors (G-CSFs), Intravenous Fluids, Antipyretics And Pain Management
What Emerging Trends Are Influencing The Growth Of The Febrile Neutropenia Market?
Prominent firms engaged in the febrile neutropenia landscape are striving to develop advanced biosimilar medications to improve treatment provision. Biosimilar drugs, being biological imitations, closely mirror approved reference drugs in their structure, functionality, and effectiveness. They provide affordable substitutes to authentic biologics, enhancing patient accessibility while adhering to strict regulatory requirements. For example, in September 2022, Fresenius Kabi, a pharmaceutical company headquartered in Germany, was granted approval by the U.S. Food and Drug Administration (FDA) for their biosimilar drug, Stimufend (pegfilgrastim-fpgk). This approval allows for Stimufend to be administered to patients suffering from non-myeloid tumors undergoing myelosuppressive chemotherapy, a treatment that can cause febrile neutropenia, a severe medical condition marked by a decrease in white blood cells and fever. Fresenius Kabi intends to introduce Stimufend in a prefilled syringe design in early 2023 and is in the process of creating an on-body injector for prospective use.
Who Are the Key Players In The Febrile Neutropenia Market?
Major companies operating in the febrile neutropenia market are:
• Pfizer Inc.
• Sanofi S.A.
• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Sandoz
• Fresenius Kabi
• Aurobindo Pharma Ltd.
• Lupin Limited
• Mundipharma GmbH
• BeyondSpring Inc.
• Hospira Inc.
• Biocon Biologics Limited
• Kyowa Kirin Co. Ltd.
• Coherus BioSciences Inc.
• Assertio Holdings Inc.
• Napp Pharmaceuticals Limited
• Gennova Biopharmaceuticals Limited
• Acrotech Biopharma Inc.
• Taiho Pharmaceutical Co. Ltd.
• Evive Biotech
What Is The Most Dominant Region In The Febrile Neutropenia Market?
North America was the largest region in the febrile neutropenia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the febrile neutropenia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.